« Back to slide 1
Continue to slide 3 »

#19. Regeneron Pharmaceuticals, Inc. (REGN) — 35% UPSIDE

Company Name:  Regeneron Pharmaceuticals, Inc.
Sector:  Biotechnology

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. Co.'s commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. Co.'s products include: EYLEA (aflibercept) injectio, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis. The median 12 month forward target price among analysts covering REGN is $403.0/share.

« Back to slide 1
Continue to slide 3 »
Quotes delayed 20 minutes
Get Free SEC filing alerts for REGN:
REGN SEC Filing Email Alerts ServiceExternal link
 

20 Growth Stocks For 2020 - Page 2 | www.RediNews.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video.